1 pharmacokinetics chapters 8 and 11. 2 pharmacokinetics and pharmacodynamics pharmacodynamics is...
Post on 21-Dec-2015
228 views
TRANSCRIPT
1
Pharmacokinetics
Chapters 8 and 11
2
Pharmacokinetics and pharmacodynamics
• Pharmacodynamics is the study of how drugs interact with a molecular target, i.e; effect of the drug on the body.
• Pharmacokinetics is the study of how a drug reaches its target in the body and how it is affected on that journey, i.e; effect of the body on the drug.
• Pharmacokinetics is the study of how is the drug absorbed, distributed, metabolized and excreted in the body
3
Pharmacokinetics & related topics
The four main issues in Pharmacokinetics are:
absorption, distribution, metabolism and excretion
4
Pharmacokinetics & related topics
Drug absorption • Refers to the route or method by which
the drug reaches the blood supply, this depends on how the drug is administered.
• The most common and preferred method of administration is the oral route.
• It depends on hydrophilic/hydrophobic properties, polarity and ionization of the drug.
5
I-Stability: ”Oral drugs have to be chemically stable to
survive the stomach HCl and metabolically
stable to survive the digestive enzymes in GIT
and metabolic enzymes in liver (mainly
cytochrome P450 ).
-Insulin, local anaesthetics and first penicillins
are acid labile , so they can't be taken orally but
are given parentrally.
Drug absorption
6
Pharmacokinetics & related topicsDrug absorption
• II-Solubility• The drug should have the correct balance of
water versus fat solubility
• Oral drugs should be sufficiently polar to dissolve in the GIT and blood supply, but sufficiently fatty to pass through the cell membranes (optimum hydrophophobic/hydrophilic balance).
• Most oral drugs obey Lipinski’s rule of five, i.e.
1-A molecular weight less than 500
2-No more than 5 hydrogen bond donor groups
3-No more than 10 hydrogen bond acceptor groups
4-A calculated log P value less than + 5
7
Pharmacokinetics & related topicsDrug absorption
• II-Solubility
A- Polarity:
• Some polar drugs break these rules are usually
poorly absorbed and have to be administered
by injection.
• Highly polar drugs will dissolve in GIT but they will fail to
be absorbed through the lipid cell membrane of the gut
wall while nonpolar drugs will be poorly soluble in the
GIT instead they will dissolve in the fat globules leading
to poor surface contact with cell membranes resulting in
poor absorption , too.
8
Pharmacokinetics & related topics
Drug absorption B-Ionization:The presence of the weak ionizable -NH- group in many drug structure would have three advantages:A- good solubility due to =NH2+ cation in stomach acidB- good absorption due to conversion to non ionized form in intestine in slightly alkaline pHC-good target interactions due to participation of ammonium ion in them
N H N
H
H
+ H+
- H+
9
Drug absorption
-Henderson-Hasselbalch equation
pH= pKa + log [A-]/[HA]
C-Size :
Large molecular weight drugs generally have
poor absorption because they mostly have a
large number of polar groups which will lead to
poor absorption of these drugs.
10
Pharmacokinetics & related topics Drug absorption
mechanisms:• Most drugs with proper solubility in
both water and lipid will be absorbed through the lipid cell membrane of the gut wall cells .
• Carrier proteins are essential to a cell’s survival as they transport highly polar building blocks required for various biosynthetic pathways.
11
Pharmacokinetics & related topics Drug absorption mechanisms:
• Some polar drugs, are absorbed by special carrier proteins such as levodopa fluorouracil, lisinopril, methotrexate and erythromycin, which are similar in structure to (or bear a structural resemblance to) one of the building blocks (such as amino acid) then it too may be smuggled into the cell
• Other polar drugs with high molecular weight are absorbed by pinocytosis (without passing through the membrane).
12
Pharmacokinetics & related topics Drug absorption mechanisms:
• Some polar drugs with low molecular weight (<200) are absorbed by passing through the pores between cells lining the gut wall.
• Thus polar drugs are orally active if they are
small enough to pass between the cells of the gut wall or are recognized by carrier proteins or are taken across the gut wall by pinocytosis.
• N.B: sometimes drugs are designed to be highly polar to be retained in the gut and not absorbed to treat gut infections as some antibacterial agents for gut infections.
13
Pharmacokinetics & related topics
• Dosage:• Drug dosing or dose regimen (regime) means drug
amount in each dose and frequency of
administration.
• Due to the number of pharmacokinetic variables
involved, it can be difficult to estimate the correct
dosing regime for a drug.
• The drug should be administered at the correct dose
levels and at frequency to ensure that blood
concentration remain within the therapeutic window.
• Therapeutic window means drug levels in blood lie
between therapeutic and toxic levels).
14
Pharmacokinetics & related topics• Dosage:
• In general, the concentration of free drug in
blood (non bound to plasma proteins) is a good
indication of the availability of that drug at its
target site.
• Other dosing complications include differences
in age, sex, race, diet, environment, obesity,
time of dosing (due to change in metabolic
rates throughout the day), drug-drug
interactions.
15
Dosage
• The half-life of a drug is the time taken for the blood concentration of the drug to fall by half. A knowledge of half-life is required to calculate how frequently doses should be given to ensure a steady state concentration.
• Drug tolerance is where the effect of a drug diminishes after repeated doses.
• In physical dependence a patient becomes dependent on a drug and suffers withdrawal symptoms on stopping the treatment.
16
Formulation of drug Formulation refers to the method by which the
drugs are prepared for administration, where by solution, pill, capsule, liposome (small vesicles consisting of a phospholipid bilayer mambrane), or microsphere (small spheres made up of a biologically degradable polymer
The way a drug is formulated can avoid some of the problems associated with oral administration.
Drugs are normally taken orally as tablets or capsules.
A tablet is a compressed preparation that contains 5-10% of the drug (active ingredient), in addition to many additives which help to ensure easy disintegration, and dissolution of the tablet in the stomach or intestine.
17
Formulation of drug
Tablet formulation can be modified to give rapid effect (sublingual tablets) or sustained release. Special coatings can make the tablet resistant to stomach acid but disintegrates only in intestine (enteric coated tablets).
Drug administration
• The main routes are oral, sublingual, rectal,
topical, epithelial, inhalation and injections. The
method chosen depends upon the target organ
and the pharmacokinetics of the drug.
18
Methods (routes )of drug administration
• Oral administration is the preferred method of administering drugs, but it is also the most demanding on the drug.
• Drugs administered by methods other than oral route avoid the first pass effect
– Oral
– Sublingual
– Rectal
– Epithelial
• Topical
• Nasal spray
• Eyedrops
– Inhalation
– Injection• Intravenous
• Subcutaneous
• Intramuscular
• Intrathecal
– Implants
19
Drug administration o Drugs can be administered such that they are
absorbed through the mucous membranes of the mouth, nose, or eyes.
o Some drugs are administered rectally as suppositories.
o Topically administered drugs are applied to the skin. Some drugs are absorbed through the skin into the blood supply.
o Inhaled drugs are administered as gases or aerosols to act directly on the respiratory system. Some inhaled drugs are absorbed into the blood supply to act systemically.
20
Drug administration
o Polar drugs which are unable to cross cell
membranes are given by injection.
o Injection is the most efficient method of
administering a drug but it also the most
hazardous. Injection can be intravenous,
intramuscular, subcutaneous, or intrathecal.
o Implants have been useful in providing
controlled drug release such that blood
concentrations of the drug remain as level as
possible. (e.g. insulin, gliadel)
21
Drug distribution• Once the drug is absorbed, it is rapidly
distributed around the blood supply, then slowly
distributed to the various tissues and organs.
• Distribution to the interstitial fluid surrounding
tissues and organs is rapid if the drug is not
bound to plasma proteins .
• Some drugs have to enter cells in order to reach
their target.
• A certain percentage of a drug may be absorbed
into fatty tissue (e.g. Barbiturates) and/or bound
to macromolecules
22
Drug distribution• Drugs entering the CNS have to cross the blood-
brain barrier. Polar drugs (e.g. Penicillin) are
unable to cross this barrier unless they make
use of carrier proteins or are taken across by
pinocytosis (e.g. insulin).
• Some drugs cross the placental barrier into the
fetus and may harm development or prove toxic
in newborn babies (e.g. alcohol, nicotine,
cocaine, barbiturates)
23
Drug-drug interactions
These are defined as the effects that one drug has on
the activity of another drug if both drugs are taken
together.
Examples are Warfarin or methotrexate bound to
albumin and plasma protein in the blood and they will
be unavailable to interact with their targets.
When another drug is taken which can compete for
plasma protein binding (e.g. sulphonamide), then a
certain percentage of previously bound drug(warfarin
or methotrexate) is released, increasing the
concentration of the drug
and its
effect.
24
Drug Metabolism• Drugs are exposed to enzyme-catalyzed
reactions which modify their structure. This is called drug metabolism and can take place in various tissues. But, most reactions occur in liver.
• Orally taken drugs are subjected to the first pass effect.
• Drugs administered by methods other than the oral route avoid the first pass effect.
• Phase I metabolic reactions typically involve the addition or exposure of a polar functional group.
25
Drug Metabolism• Cytochrome P450 enzymes present in the liver
carry out important phase I oxidation reactions. The type of cytochrome P450 enzymes present vary between individuals, leading to varying rates of metabolism.
• The activity of cytochrome P450 enzymes can be affected by food, chemicals, and drugs, resulting in drug-drug interactions and possible side effects.
• Phase II metabolic reactions involve the addition of highly polar molecules to a functional group. The resulting conjugate are more easily excreted.
26
Drug Excretion
• Drugs excretion can take place through sweat, exhaled air, or bile, but most excretion takes place through the kidneys.
• The kidneys filter blood such that drugs and their metabolites enter nephrons.
• Non-polar substances are reabsorbed into the blood supply, but polar substances are retained in the nephrons and excreted in urine.
27
To control chemical and physical properties…
• Drug design
• Alter functional groups
• Quantitative SARs
• Computational methods
28
Solubility
• Hydrophobic/hydrophilic balance:• The hydrophobic/hydrophilic character of the drug is the
crucial factor affecting absorption through the gut wall.
• Decrease polarityBy masking a polar functional
group with an alkyl or acyl group.
• Increase polarityBy adding a polar orMore polarfunctional group to a drug to increase its
polarity.
• Ionization
R OH O CR OR' R'
O
or
R C OR'
O
R C OH
O
R
F
N
N
N
HO
N
NN
F
Cl
NN
H
O
Cl
SCl
(I)Ticonazole -----------------------(II)Fuconazole
29
Stability• Option A: Make drugs more resistant
to metabolism and hydrolysis1. Steric shield• Some functional groups are susceptible to
chemical and enzymatic degradation than others.
• To protect such groups, a steric shield designed to hinder the approach of a nucleophile or enzyme to those groups is added.
• These usually involve the addition of a bulky alkyl group close to the functional group. E.g., t-butyl group.
R
O
R'
O
R
O
R'
O
C CH3
CH3
CH3
30
Stability
2- Bioisosteres To protect a labile functional group by
stabilizing it electronically using a bioisostere.
Using bioisostere is to replace a chemical
group within the drug with another chemical
group (of the same size and valency but
with different electronic property) without
affecting the important biological activity. This
may also improve drug’s stability.
O
C
OCH3
R
O
C
OH2N
R
31
Stability3- Stereo electronic modification This means steric hinderance together with
electronic stabilization are used stabilize labile groups.
Example: lidocaine from procaine Proocaine is short lasting due to quick
hydrolysis of its ester group. Changing this ester group into less reactive amide reduces chemical hydrolysis.
Moreover, the presence of two o-methyl groups on aromatic ring provides a steric shield for the carbonyl group.
NH2
O
N
O
NH
N
O
CH3CH3
Lidocaine
Proocaine ornovocaine
32
Stability4. Metabolic blockers Example: Some drugs are
metabolized by the introduction of polar groups at particular positions in their skeleton.
Megestrol acetate is oxidized at position 6 to give a hydroxyl group, leading to quick elimination of the water soluble conjugate.
By introducing a methyl group in its analogue at this position, metabolism is blocked and its action is prolonged.
R R' R R'
OH
R R'
CH3
Ox
Ox
O
O O
H
H H
O
Megestrol acetate analogue
33
Stability5. Remove metabolic
groups• Certain chemical groups
are susceptible to metabolic enzymes.
• Example: CH3-group on aromatic ring are often oxidized into –COOH, which can be quickly eliminated from the body.
• These groups are either removed or replaced by groups that are stable to oxidation to prolong the lifetime of the drug.
CH3 CO2H
OH
Cl
Ox
Ox
Ox
34
Stability5. Remove metabolic groups Chlorpropamide from tolbutamide
CH3 group was replaced by Cl atom and
action is more prolonged.
H3C S
O
O
NH
O
NH
Cl S
O
O
NH
O
NH
ChlorpropamideTolbutamide
35
Stability
6. Group Shifts
When a vulnerable chemical group can’t be replaced or removed because it is involved in important binding interactions with the binding site, we have two possible solutions.
One is to mask this group temporarily by using a prodrug. The second is to try shifting this group within the molecular skeleton.
OH OCH3metabolize
metabolizeOH
36
Stability6. Group Shifts
Example: Salbutamol from noradrenaline, where in noradrenaline, both phenolic groups are involved in hydrogen bonding to the receptor, thus
metabolic methylation of one of these groups makes the compound inactive and has a short duration.
A solution is to move one phenolic group out from the ring by one carbon unit only (if more, activity is lost, due to improper binding)HO
OH
OH
NH
C(CH3)3
HO
HO
OH
NH2
Salbutamol
Noradrenaline
37
Stability
• Option B: Make drugs less resistant to metabolism:
• A drug that is extremely stable to metabolism and is very slowly excreted can pose just as many problems as one that is susceptible to metabolism.
• If the effects of the drug could last too long then it would cause both:
→ Toxicity→ Lingering side effects Therefore, designing drugs with decreased
chemical and metabolic stability can sometimes be useful. This is called shortening the lifetime of the drug.
38
Other factors in drug design
• Reducing Toxicity:
• A drug fails clinical trials because of its toxic
side effects. This may be due to toxic
metabolites.
• Thus, the drug should be made more resistant
to metabolism by knowing functional groups
prone to producing toxic metabolites and
removing them or changing them into harmless
substituents or varying their position.
39
Other factors in drug design
• Prodrugs:• Prodrugs are inactive
compounds but which are converted in the body into
the active drug
• I-Valium (more sustained action) → nordazepam:
• Valium sedative is believed to be a prodrug and is metabolized by N-demethylation into Nordazepam. The latter has been used as a sedative, but loses activity by metabolism and excretion.
O
N
Cl
N
Valium
O
N
Cl
NH
Nordiazepam
N-demethylation
40
Other factors in drug design• Prodrugs:
II-L-dopa → dopamine (approach for carrier protein):
prodrug---→ active drug– Levodopa is a prodrug for the
neurotransmitter dopamine which is used in Parkinson’s disease. levodopa is much more polar than dopamine but yet it can cross the BBB because it is an amino acid and is recognized by the carrier proteins for amino acids. NH2HO
HO
dopamine
NH2
O OH
phenylalanine
NH2
O OH
levodopa
HO
HO
41
Other factors in drug design• Prodrugs:
III-Aspirin → salicylic acid:To mask drug toxicity and side effectsSalicylic acid is a good painkiller but causes
gastric bleeding due to phenolic OH which is converted into an ester in aspirin. The ester is later hydrolysed to free the active drug.
Also, aspirin is an antiinflammatory action.
OH
OH
O
salicylic acid
O
OH
O
O
aspirin
42
Sentry drugsA second drug is administered alongside the principal
drug where the role of the second drug is to guard or assist the principal drug.
1- Carbidopa:Levodopa is a prodrug for dopamine but large doses are required to be effective due to its Decarboxylation before it reaches the CNS .Carbidopa is an inhibitor of dopa decarboxylaseAnd thus it allows smaller doses of levodopa to be used
with lower side effects. Furthermore, carbidopa is highly polar so it can’t pass BBB where the decarboxylation of levodopa is required.
INHIBITIONINHIBITION
CNHNH2
HO
Me
HO
CO2H
L-DOPA DOPAMINEENZYME
43
• Sentry drugs
2- Clavulanic acid and amoxicillin
Clavulanic acid inhibits the enzyme β-lactamase in microorganisms and is therefore able to protect penicillins (amoxicillin) from that particular microbial enzyme.
O
SH
HN
R
O
N
O
OH
O
OH
N
O
OH
H
OH